Neoleukin Therapeutics Inc

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbol "NGNE" following the anticipated closing of the merger with Neurogene Inc. (the “Merger”), with a new CUSIP number 64135M105. The reverse stock split was effected to ensure the combined company's compliance with the minimum bid price requirement of $4.00 per share for initial listing on the Nasdaq Global Market. The reverse stock split was approved by Neoleukin's stockholders at the Company's special meeting of stockholders held on December 13, 2023, to be effected in the Board's discretion within approved parameters of not less than 1-for-1.5 and not more than 1-for-5. The final reverse stock split ratio was approved by the Board on December 13, 2023. The reverse stock split is expected to reduce the number of shares of the Company's outstanding common stock from approximately 9,398,497 shares to approximately 2,349,624 shares. The number of shares of the Company's authorized common stock was not affected by the reverse stock split, but at the special meeting of stockholders, Neoleukin's stockholders approved an increase in the number of shares of the Company's authorized common stock from 20,000,000 shares to 500,000,000 shares in connection with the anticipated closing of the Merger. As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Neoleukin's common stock underlying the Company's outstanding equity awards and pre-funded warrants for common stock, as well as the number of shares of common stock issuable under the Company's equity incentive plan and employee stock purchase plan. There will be no change to the par value per share.

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin's common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin's existing trading symbol “NLTX” with a new CUSIP number 64049K203. The reverse stock split is part of Neoleukin's plan to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Neoleukin Therapeutics, Inc. (NasdaqCM: NLTX) with Neurogene Inc. Under the terms of the proposed transaction, pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company (subject to certain adjustments) and will also be issued contingent value rights to receive certain pa.

NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX

MILWAUKEE , July 18, 2023 /PRNewswire/ -- Ademi LLP is investigating Neoleukin (Nasdaq: NLTX) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Neurogene.  Click here to learn how to join the action https://www.ademilaw.com/case/neoleukin-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) and Neurogene Inc. is fair to Neoleukin shareholders. Pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company. Halper Sadeh encourages Neoleukin shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.

NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders

NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, and Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene's pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile. Upon completion of the merger, which is subject to approval by Neurogene and Neoleukin stockholders, the combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol “NGNE”.

Neurogene and Neoleukin Announce Definitive Merger Agreement

Neoleukin Therapeutics: Strategic Review Play

Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.

Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan

Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday.

Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger

SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Neoleukin does not expect to disclose or provide an update concerning developments related to this process until the Company enters into definitive agreements or arrangements with respect to a transaction or otherwise determines that other disclosure is necessary or appropriate.

Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition

Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells

Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting

Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.

Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down

-- Development of NL-201 to be discontinued for strategic reasons -- -- Company to focus on next-generation de novo proteins and core technology -- -- Company restructuring to extend cash runway into the second half of 2025 -- SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de novo IL-2/IL-15 agonist, and focus on advancing next-generation de novo protein therapeutics based on Neoleukin's expertise in designing and testing novel cytokine mimetics and experience with advanced machine learning.

Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana.

Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor Relations Jonathan Drachman - Chief Executive Officer Priti Patel - Chief Medical Officer Sean Smith - Vice President, Finance Conference Call Participants Mary Kate - Bank of America Charles Zhu - Guggenheim Securities Ben Burnett - Stifel Mara Goldstein - Mizuho Securities Operator Good afternoon and thank you for joining us today for the Neoleukin Therapeutics Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call Transcript

Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30 p.m. Eastern Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30 p.m. Eastern

Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update

SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:

Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2022 and provided a corporate update.

Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update

SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows:

Neoleukin Therapeutics to Present at Upcoming Investor Conferences

- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models -

Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern.

Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, Louisiana.

Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript

- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 –

Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

- NL-201 plus pembrolizumab to be evaluated in advanced solid tumor patients - - Combination testing anticipated to begin in 2022 -

News for Neoleukin Therapeutics Inc Stock (NLTX)